All articles tagged with #telehealth
Live updates show medical providers, including Dr. Jennifer Tufts, being cross-examined as Lindsay Clancy’s murder trial focuses on whether telehealth and treatment decisions influenced her deteriorating mental health; prosecutors allege a systemic failure to diagnose and treat her condition, while the defense argues postpartum psychosis and overmedication played a role in the killings.
In the Lindsay Clancy murder case, her psychiatrist testified that all sessions with Clancy were conducted via telehealth and she had never met her in person, limiting her ability to observe physical cues (hands/legs). The defense questioned potential misrepresentation of postpartum specialization and whether hospital records were reviewed, noting Clancy’s claims of worsening symptoms and prior hospital visits. The psychiatrist disputed malpractice allegations, saying sessions lasted 25–30 minutes and she provided support, though she did not review hospital records and did not see signs of psychosis in clinic notes.
Chrissy Metz reveals she’s started a GLP-1 medication through Ro after initial skepticism. She says the therapy has quieted her food thoughts, boosted stamina for eight shows a week on Broadway, and even improved inflammation and joint comfort, with her menstrual cycle regulating and body measurements changing enough to require costume tweaks. Metz stresses it isn’t a magic fix, urges careful research and doctor consultation, and notes she expects scrutiny while pursuing long‑term health, including considerations around perimenopause.
STAT reports a leadership exodus at Epic, highlighted by Sumit Rana’s departure and other executive exits, fueling questions about the company’s direction amid health-tech talent churn; the issue also covers LifeMD’s GLP-1 telehealth controversy, Nabla naming a new CEO as AI competition intensifies, notable hires across Aledade and TytoCare, and a broader health-tech funding and policy roundup.
A NBC News and KFF Health News investigation finds safety gaps in telehealth prescribing of GLP-1 weight-loss drugs, highlighted by a North Carolina woman who was hospitalized after an overdose from dosing instructions she received online. With about 11% of U.S. adults using GLP-1s and a 1,500% increase in overdose/side-effect calls to poison centers from 2019–2025, experts warn that telehealth can lack critical oversight and proper dosing checks, particularly with compounded drugs not reviewed by the FDA. Advocates urge stronger provider access, clearer dosing protocols, and safer sourcing to protect patients.
A Yale secret-shopping study in which a Yale medical student posed as a 237-pound patient found that most online GLP-1 weight-loss drug vendors provide lax clinical oversight; only 13 of 49 sites required video consultations, with many relying on unverified online questionnaires, raising patient-safety concerns amid the GLP-1 drug boom.
GLP-1 diabetes/weight‑loss drugs are seeing a rise in life‑threatening overdoses as use has surged since 2021 and telehealth lowers barriers to access, sometimes bypassing in-person care. Poison‑control calls jumped from about 100 monthly in 2021 to roughly 1,000 by 2025, with patients suffering severe vomiting, dehydration, seizures, and even vomiting blood. Compounded or online‑sourced versions can have inconsistent dosing and less doctor oversight, prompting FDA warnings about unregulated products. Experts urge caution, proper dosing, and urgent care for severe symptoms, noting risks like pancreatitis and hypoglycemia, with children also at risk.
The Supreme Court allowed the continued mailing and telehealth dispensing of mifepristone while the case plays out, but conservative Justices Thomas and Alito dissented, warning that enforcing the 1873 Comstock Act could threaten broader abortion access and hinting at a renewed federal abortion ban push. The decision preserves a critical lifeline for medication abortion in the near term, though advocates warn the threat to access remains tied to ongoing regulatory reviews, potential political maneuvering ahead of the midterms, and the Dobbs framework that eliminated a nationwide abortion right. Medication abortions already account for a large share of U.S. procedures, and while misoprostol-alone options exist, experts note they are less convenient and carry more side effects. This remains a high-stakes, politically charged battleground for abortion access.
The Supreme Court issued a brief order allowing the abortion pill mifepristone to continue to be prescribed via telehealth and mailed to patients, blocking a Fifth Circuit ruling while litigation continues in lower courts. The decision preserves access for now as Louisiana’s challenge to FDA rules proceeds, with justices Thomas and Alito dissenting; the case centers on whether the FDA’s loosened 2021 regulations were properly grounded amid ongoing safety reviews and regulatory scrutiny.
The Supreme Court blocked a lower-court order that would have halted mailing mifepristone, allowing telehealth prescriptions for the abortion pill to continue while Louisiana challenges its legality. Mailed access has contributed to rising telehealth abortions—about a quarter of all abortions and half of those in states with bans—amid ongoing legal fights that could reach the Court again, with dissents from Justices Thomas and Alito criticizing the decision.
The Supreme Court temporarily preserved access to mifepristone—allowing it to be dispensed via telehealth, mail, or pharmacies without in-person doctor visits—while a Louisiana-led lawsuit against FDA rules proceeds, leaving current access arrangements in place for now and likely into the next year as the case unfolds.
The Supreme Court temporarily preserves access to the abortion pill mifepristone by allowing telehealth visits and mail distribution to continue, maintaining the status quo while Louisiana’s challenge proceeds in the federal courts; the court paused a May 1 ruling requiring in-person visits, Justices Thomas and Alito dissented, and the merits will likely be reviewed again in the appeals court before any final ruling.
Hims & Hers Health posted first-quarter revenue of $608 million and a loss of $0.40 per share, missing expectations of $616.8 million and $0.03, which sent the stock down as much as 10% after hours. The company raised its full-year revenue guidance to about $2.8–3.0 billion from a prior range, with Q2 revenue seen around $2.7 billion by analysts. The results come amid regulatory scrutiny after a Wegovy-like rollout was pulled following a Novo Nordisk lawsuit, and ongoing GLP-1 drug partnerships with Novo Nordisk. Analysts maintain a Moderate Buy rating with a $28.02 price target, implying modest downside from current levels.
The Supreme Court on Monday extended a short-term stay allowing patients to continue obtaining the abortion pill mifepristone via telehealth visits and mail through Thursday at 5 p.m. ET, while it weighs an emergency appeal. The extension preserves access after the 5th Circuit had ordered in-person visits, a ruling that sparked chaos for providers. The case ties FDA policy on mifepristone to the broader Dobbs era of abortion politics, with Louisiana challenging the FDA and both Danco Laboratories and GenBioPro filing emergency appeals.
After the 5th Circuit reinstated a requirement that mifepristone be dispensed in person, abortion-rights advocates warned telehealth access could falter. While that concern persists, many providers say they’ve prepared contingency plans—relying on in-person dispensing options where possible and adapting telehealth protocols—to preserve access as legal battles continue.